3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
CNS
1
Conditions
Brain Neoplasms
12
Glioblastoma
11
Glioma
6
Neoplasm Metastasis
4
Carcinoma, Renal Cell
4
Astrocytoma
4
Oligodendroglioma
3
Meningioma
3
Gliosarcoma
3
Paraganglioma
2
Melanoma
2
Kidney Neoplasms
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neurofibromatosis 2
1
Neurofibromatosis 1
1
Neurofibromatoses
1
Neoplasms
1
Multiple Myeloma
1
Interventions
3-Iodobenzylguanidine
13
lutetium Lu 177 dotatate
5
gallium Ga 68 dotatate
4
Temozolomide
4
Specimen Handling
4
anlotinib
3
Magnetic Resonance Spectroscopy
3
Everolimus
3
pegfilgrastim
2
olaparib
2
cabozantinib
2
belzutifan
2
Radiotherapy
2
Phenoxybenzamine
2
Nivolumab
2
Granulocyte Colony-Stimulating Factor
2
Fluorodeoxyglucose F18
2
Biopsy
2
Axitinib
2
3-fluorobenzylguanidine
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
vandetanib
1
tipifarnib
1
temsirolimus
1
talazoparib
1
spartalizumab
1
pentetreotide
1
penpulimab
1
pembrolizumab
1
pazopanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pheochromocytoma
×
Sunitinib
×
CNS
×
Clear all
NCT00843037
2024-10-17
SNIPP
University Health Network, Toronto
Phase 2
Completed
25 enrolled
19 charts